A S Adams1, J A Schmittdiel1, A Altschuler1, E A Bayliss2,3, R Neugebauer1, L Ma1, W Dyer1, J Clark1, B Cook1, D Willyoung1, M Jaffe4, J D Young5, E Kim5, J M Boggs2, L A Prosser6, E Wittenberg7, B Callaghan8, M Shainline2, R M Hippler1, R W Grant1. 1. Kaiser Permanente Division of Research, Oakland, CA. 2. Kaiser Permanente Colorado Institute for Health Research, Denver, CO. 3. University of Colorado School of Medicine, Denver, CO. 4. Kaiser Permanente South San Francisco Medical Center, South San Francisco, CA. 5. Kaiser Permanente Oakland Medical Center, Oakland, CA. 6. University of Michigan, School of Public Health, Ann Arbor, MI. 7. Harvard School of Public Health, Boston, MA. 8. University of Michigan, Michigan Medicine, Neurology Clinic, Ann Arbor, MI, USA.
Abstract
AIMS: To evaluate the effectiveness of automated symptom and side effect monitoring on quality of life among individuals with symptomatic diabetic peripheral neuropathy. METHODS: We conducted a pragmatic, cluster randomized controlled trial (July 2014 to July 2016) within a large healthcare system. We randomized 1834 primary care physicians and prospectively recruited from their lists 1270 individuals with neuropathy who were newly prescribed medications for their symptoms. Intervention participants received automated telephone-based symptom and side effect monitoring with physician feedback over 6 months. The control group received usual care plus three non-interactive diabetes educational calls. Our primary outcomes were quality of life (EQ-5D) and select symptoms (e.g. pain) measured 4-8 weeks after starting medication and again 8 months after baseline. Process outcomes included receiving a clinically effective dose and communication between individuals with neuropathy and their primary care provider over 12 months. Interviewers collecting outcome data were blinded to intervention assignment. RESULTS: Some 1252 participants completed the baseline measures [mean age (sd): 67 (11.7), 53% female, 57% white, 8% Asian, 13% black, 20% Hispanic]. In total, 1179 participants (93%) completed follow-up (619 control, 560 intervention). Quality of life scores (intervention: 0.658 ± 0.094; control: 0.653 ± 0.092) and symptom severity were similar at baseline. The intervention had no effect on primary [EQ-5D: -0.002 (95% CI -0.01, 0.01), P = 0.623; pain: 0.295 (-0.75, 1.34), P = 0.579; sleep disruption: 0.342 (-0.18, 0.86), P = 0.196; lower extremity functioning: -0.079 (-1.27, 1.11), P = 0.896; depression: -0.462 (-1.24, 0.32); P = 0.247] or process outcomes. CONCLUSIONS:Automated telephone monitoring and feedback alone were not effective at improving quality of life or symptoms for people with symptomatic diabetic peripheral neuropathy. TRIAL REGISTRATION: ClinicalTrials.gov (NCT02056431).
RCT Entities:
AIMS: To evaluate the effectiveness of automated symptom and side effect monitoring on quality of life among individuals with symptomatic diabetic peripheral neuropathy. METHODS: We conducted a pragmatic, cluster randomized controlled trial (July 2014 to July 2016) within a large healthcare system. We randomized 1834 primary care physicians and prospectively recruited from their lists 1270 individuals with neuropathy who were newly prescribed medications for their symptoms. Intervention participants received automated telephone-based symptom and side effect monitoring with physician feedback over 6 months. The control group received usual care plus three non-interactive diabetes educational calls. Our primary outcomes were quality of life (EQ-5D) and select symptoms (e.g. pain) measured 4-8 weeks after starting medication and again 8 months after baseline. Process outcomes included receiving a clinically effective dose and communication between individuals with neuropathy and their primary care provider over 12 months. Interviewers collecting outcome data were blinded to intervention assignment. RESULTS: Some 1252 participants completed the baseline measures [mean age (sd): 67 (11.7), 53% female, 57% white, 8% Asian, 13% black, 20% Hispanic]. In total, 1179 participants (93%) completed follow-up (619 control, 560 intervention). Quality of life scores (intervention: 0.658 ± 0.094; control: 0.653 ± 0.092) and symptom severity were similar at baseline. The intervention had no effect on primary [EQ-5D: -0.002 (95% CI -0.01, 0.01), P = 0.623; pain: 0.295 (-0.75, 1.34), P = 0.579; sleep disruption: 0.342 (-0.18, 0.86), P = 0.196; lower extremity functioning: -0.079 (-1.27, 1.11), P = 0.896; depression: -0.462 (-1.24, 0.32); P = 0.247] or process outcomes. CONCLUSIONS: Automated telephone monitoring and feedback alone were not effective at improving quality of life or symptoms for people with symptomatic diabetic peripheral neuropathy. TRIAL REGISTRATION: ClinicalTrials.gov (NCT02056431).
Authors: Mary Reed; Jie Huang; Ilana Graetz; Richard Brand; John Hsu; Bruce Fireman; Marc Jaffe Journal: Ann Intern Med Date: 2012-10-02 Impact factor: 25.391
Authors: David S Oyer; Mark D Shepherd; Franklin C Coulter; Anuj Bhargava; Jason Brett; Pei-Ling Chu; Bruce S Trippe Journal: Am J Med Date: 2009-11 Impact factor: 4.965
Authors: Alyce S Adams; Elizabeth A Bayliss; Julie A Schmittdiel; Andrea Altschuler; Wendy Dyer; Romain Neugebauer; Marc Jaffe; Joseph D Young; Eileen Kim; Richard W Grant Journal: Clin Trials Date: 2016-03-31 Impact factor: 2.486
Authors: David Hohenschurz-Schmidt; Bethea A Kleykamp; Jerry Draper-Rodi; Jan Vollert; Jessica Chan; McKenzie Ferguson; Ewan McNicol; Jules Phalip; Scott R Evans; Dennis C Turk; Robert H Dworkin; Andrew S C Rice Journal: Pain Date: 2022-01-01 Impact factor: 6.961